
Surmodics SRDX
Quarterly report 2025-Q2
added 08-08-2025
Surmodics Book Value 2011-2026 | SRDX
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value Surmodics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 119 M | 120 M | 108 M | 140 M | 131 M | 123 M | 109 M | 112 M | 107 M | 91.9 M | 98.8 M | 93.8 M | 93.7 M | 145 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 145 M | 91.9 M | 114 M |
Quarterly Book Value Surmodics
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 111 M | 110 M | 112 M | 119 M | 118 M | 124 M | 122 M | 120 M | 112 M | 103 M | 107 M | 108 M | - | 133 M | 137 M | 140 M | 141 M | 140 M | 133 M | 131 M | 131 M | 131 M | 123 M | 123 M | 123 M | 123 M | 114 M | 109 M | 109 M | 109 M | 111 M | 112 M | 112 M | 112 M | 107 M | 107 M | 107 M | 107 M | 95.3 M | 91.9 M | 91.9 M | 91.9 M | 81.7 M | 98.8 M | 98.8 M | 98.8 M | 88.9 M | 93.8 M | 93.8 M | 93.8 M | 98.7 M | 95 M | 95 M | 93.7 M | 143 M | 140 M | 140 M | 140 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 143 M | 81.7 M | 113 M |
Book Value of other stocks in the Diagnostics research industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
77.2 M | - | -6.23 % | $ 30.6 M | ||
|
Akumin
AKU
|
141 M | - | -17.87 % | $ 25.9 M | ||
|
Aspira Women's Health
AWH
|
6.73 M | - | -6.19 % | $ 10.5 M | ||
|
Bioventus
BVS
|
228 M | $ 9.0 | 1.47 % | $ 600 M | ||
|
Brainsway Ltd.
BWAY
|
75.7 M | $ 13.99 | 2.49 % | $ 99.4 M | ||
|
Castle Biosciences
CSTL
|
456 M | $ 26.24 | 1.59 % | $ 729 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
16.7 M | - | - | $ 562 M | ||
|
Charles River Laboratories International
CRL
|
3.21 B | $ 154.17 | 1.45 % | $ 7.64 B | ||
|
DexCom
DXCM
|
2.75 B | $ 68.54 | 3.32 % | $ 26.7 B | ||
|
CareDx, Inc
CDNA
|
303 M | $ 17.77 | 2.6 % | $ 947 M | ||
|
Guardant Health
GH
|
-99.3 M | $ 88.16 | 1.12 % | $ 11.1 B | ||
|
Accelerate Diagnostics
AXDX
|
-22.3 M | - | -61.36 % | $ 2.46 M | ||
|
Exact Sciences Corporation
EXAS
|
2.4 B | $ 103.95 | 0.1 % | $ 19.6 B | ||
|
Global Cord Blood Corporation
CO
|
4.88 B | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
132 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
16.4 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
548 M | - | 0.12 % | $ 80.1 M | ||
|
Fulgent Genetics
FLGT
|
1.13 B | $ 15.57 | 4.15 % | $ 471 M | ||
|
PRA Health Sciences, Inc.
PRAH
|
1.32 B | - | - | $ 10.7 B | ||
|
Biodesix
BDSX
|
20.9 M | $ 17.22 | -0.4 % | $ 2.23 B | ||
|
ICON Public Limited Company
ICLR
|
9.52 B | $ 101.08 | 3.55 % | $ 8.34 B | ||
|
Anixa Biosciences
ANIX
|
14 M | $ 2.88 | 1.23 % | $ 93.5 K | ||
|
IQVIA Holdings
IQV
|
6.63 B | $ 169.85 | 3.01 % | $ 29.2 B | ||
|
Danaher Corporation
DHR
|
83.5 B | $ 195.65 | 2.23 % | $ 139 B | ||
|
Biocept
BIOC
|
8.86 M | - | -13.05 % | $ 7.29 M | ||
|
Heska Corporation
HSKA
|
422 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
5.39 M | - | -20.0 % | $ 1.06 M | ||
|
Illumina
ILMN
|
6.3 B | $ 121.72 | 2.04 % | $ 19.4 B | ||
|
Quest Diagnostics Incorporated
DGX
|
16.2 B | $ 198.39 | -0.28 % | $ 22 B | ||
|
QIAGEN N.V.
QGEN
|
6.15 B | - | - | $ 10.6 B | ||
|
Agilent Technologies
A
|
5.39 B | $ 113.9 | 1.85 % | $ 34.6 B | ||
|
BioNano Genomics
BNGO
|
35.4 M | $ 1.12 | 0.91 % | $ 1.42 M | ||
|
DarioHealth Corp.
DRIO
|
96.4 M | $ 9.28 | 10.24 % | $ 263 M | ||
|
NeoGenomics
NEO
|
837 M | $ 8.39 | 1.76 % | $ 1.07 B | ||
|
Neogen Corporation
NEOG
|
2.07 B | $ 9.45 | 3.73 % | $ 2.05 B | ||
|
Lantheus Holdings
LNTH
|
1.09 B | $ 78.83 | 0.41 % | $ 5.32 B | ||
|
Chembio Diagnostics
CEMI
|
17.8 M | - | 0.22 % | $ 16.8 M | ||
|
Check-Cap Ltd.
CHEK
|
-1.45 M | - | - | $ 9.42 M | ||
|
Pacific Biosciences of California
PACB
|
5.35 M | $ 1.41 | 3.68 % | $ 423 M | ||
|
Co-Diagnostics
CODX
|
86 M | $ 4.4 | 101.83 % | $ 129 M | ||
|
Medpace Holdings
MEDP
|
459 M | $ 458.61 | 1.1 % | $ 13.2 B | ||
|
Motus GI Holdings
MOTS
|
2.69 M | - | -34.28 % | $ 263 K | ||
|
Mettler-Toledo International
MTD
|
-23.6 M | $ 1 220.43 | 1.77 % | $ 25.2 B | ||
|
Celcuity
CELC
|
116 M | $ 115.07 | 0.15 % | $ 4.54 B | ||
|
DermTech
DMTK
|
57.2 M | - | -11.32 % | $ 2.94 M | ||
|
National Research Corporation
NRC
|
14 M | $ 18.31 | 5.23 % | $ 410 M | ||
|
Invitae Corporation
NVTA
|
102 M | - | - | $ 21.2 M | ||
|
Enzo Biochem
ENZ
|
56.1 M | - | -8.98 % | $ 14.8 K | ||
|
Natera
NTRA
|
706 M | $ 201.15 | 1.76 % | $ 19.8 B | ||
|
OPKO Health
OPK
|
1.37 B | $ 1.2 | 0.84 % | $ 833 M |